Engineering life
Cell and organ
therapies, for every patient.
We unite multiplex genome editing, hypoimmunity engineering and precision delivery to bring advanced therapies within reach of more patients.
Our mission
Making cell therapies universally accessible.
To transform the treatment of severe diseases by integrating multiplex gene editing, hypoimmunity engineering, and targeted in vivo delivery, unlocking universally accessible cell therapies.
About Qihan- Cell therapies
- Islet cells
- Cardiomyocytes
- Neurons
- Immune cells
- Organ therapies
- Kidney
- Intestine
- Heart
- Lung
- Liver
- Skin
Technology platforms
View all platformsHigh-throughput genome editing
HELIX®
Our foundational platform edits multiple genes in a single step to support the development of cell therapies.
Explore HELIX®
Development
pipeline.
In vivo and allogeneic CAR-T programs for cancer and autoimmune diseases.
Investigational candidates across our pipeline
Newsroom
- Regulatory
China’s NMPA clears QT-019C for clinical testing
- Regulatory
Qihan completes a pre-IND meeting with the FDA for an in vivo CAR-T candidate
- Clinical development
Qihan completes Phase I enrollment for its allogeneic CAR-T study
In the media
Yiyao Guanlan · November 2023
Yiyao Guanlan interviews Qihan on its next steps in cell and organ therapyBioWorld · March 2021
BioWorld covers Qihan’s $67 million financing for cell and organ therapies
Life at Qihan
Employee voices
International collaboration
“opportunities for career development”
Cecilia describes international collaboration and career growth, with the shared ambition of bringing hope to patients.
Selected excerpts and summaries.
Contact us
Let's build the future of medicine together.
Hangzhou Qihan Biotech Co., Ltd.
5th Floor, Building B, Chuanhuakechuang Mansion, Xiaoshan Innovation Polis, Xiaoshan District, Hangzhou 311200, China
Fax 0571-83500370